Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
暂无分享,去创建一个
James Theiler | Eoin Coakley | Bette Korber | Chien-Chi Lo | Brian Gaschen | Chad Nusbaum | Roger Paredes | Wayne Greaves | Daniel R. Kuritzkes | Ramy Arnaout | Carsten Russ | Roy M. Gulick | Michael D. Hughes | Charles Flexner | C. Nusbaum | C. Russ | M. Hughes | B. Korber | J. Theiler | R. Paredes | D. Kuritzkes | R. Arnaout | C. Flexner | T. Leitner | B. Gaschen | C. Lo | Z. Su | A. Tsibris | R. Gulick | E. Coakley | W. Greaves | Thomas Leitner | Athe M. N. Tsibris | Zhaohui Su | Athe Tsibris | Zhaohui Su
[1] C. Nusbaum,et al. Quality scores and SNP detection in sequencing-by-synthesis systems. , 2008, Genome research.
[2] M. Ronaghi,et al. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.
[3] M. Hughes,et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. , 2007, The Journal of infectious diseases.
[4] M. Ronaghi,et al. A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.
[5] Tobias Sing,et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates , 2007, AIDS.
[6] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[7] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[8] Wei Shao,et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase , 2008, AIDS.
[9] L. M. Mansky,et al. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.
[10] P. Vernazza,et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.
[11] Robyn L Stanfield,et al. Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor , 2004, Journal of Virology.
[12] C. Broder,et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.
[13] Bernard Hirschel,et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. , 2008, The New England journal of medicine.
[14] B. Cullen,et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. , 1991, Science.
[15] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[16] Christos J. Petropoulos,et al. Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.
[17] John P. Moore,et al. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41 , 2009, Proceedings of the National Academy of Sciences.
[18] Sarah Palmer,et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.
[19] Mike Youle,et al. Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir , 2006, Journal of Virology.
[20] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[21] J. Margolick,et al. Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.
[22] Thomas LaFramboise,et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing , 2006, Nature Medicine.
[23] M. Hirsch,et al. Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1 , 2005, Antimicrobial Agents and Chemotherapy.
[24] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[25] Francoise F Giguel,et al. In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject , 2008, Journal of Virology.
[26] Anders Karlsson,et al. Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.
[27] S Bonhoeffer,et al. Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[28] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[29] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[30] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[31] B. Korber,et al. Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.
[32] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.